Latest news

4 Dec 2019 Lung
US FDA approves atezolizumab plus chemotherapy for metastatic NSCLC
3 Dec 2019 Prostate
Potential prostate cancer treatment targets genetic mutations
28 Nov 2019 News
Pembrolizumab could extend survival for prostate cancer ‘super responders’
25 Nov 2019 Head and neck
Pembrolizumab approved as standard first-line therapy for head and neck cancer

Video

View all videos

9 Sep 2019 Lung
Lung Cancer Ambition Alliance with Giorgio Scagliotti

Video

View all videos

Features

Stay up to date

Upcoming event

Molecular Analysis for Personalised Therapy Congress 2020

October 8, 2020 – October 10, 2020

Amsterdam, Netherlands

View all

Upcoming event

ESMO World Congress of Gastrointestinal Cancer 2020

July 1, 2020 – July 4, 2020

Barcelona, Spain

View all

Tweets

Oncology Central @OncologyCentral·

What resources do we require to achieve precision medicine in oncology? Watch our panel discussion featuring @RobinL_Jones ,@BettinaRyll ,@Niven_Narain , @garczaru and William Audeh from @Agendia

https://t.co/FztvflMw8E

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Our mission statement

At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.

Learn more

US FDA approves atezolizumab plus chemotherapy for metastatic NSCLC

Potential prostate cancer treatment targets genetic mutations

Pembrolizumab could extend survival for prostate cancer ‘super responders’

Pembrolizumab approved as standard first-line therapy for head and neck cancer

Highlights from the 2019 NCRI Cancer Conference

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: updated analysis of the observational GioTag study

Pharma, President, Patients: the cancer cost conundrum

How could a “pre-cancer genome atlas” transform cancer prevention?

Panel discussion: the future of oncology

The future of liquid biopsies: an interview with Bob Li

Unlocking the power of the cancer genome: an interview with Phil Febbo, Illumina Inc.

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

Video

Lung Cancer Ambition Alliance with Giorgio Scagliotti

Video

Login

Latest news

US FDA approves atezolizumab plus chemotherapy for metastatic NSCLC

Potential prostate cancer treatment targets genetic mutations

Pembrolizumab could extend survival for prostate cancer ‘super responders’

Pembrolizumab approved as standard first-line therapy for head and neck cancer

Featured articles

Highlights from the 2019 NCRI Cancer Conference

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: updated analysis of the observational GioTag study

Pharma, President, Patients: the cancer cost conundrum

How could a “pre-cancer genome atlas” transform cancer prevention?

Panel discussion: the future of oncology

The future of liquid biopsies: an interview with Bob Li

Unlocking the power of the cancer genome: an interview with Phil Febbo, Illumina Inc.

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

Video

Lung Cancer Ambition Alliance with Giorgio Scagliotti

Video

In Focus: lung cancer

Accelerating biomarker-guided drug development with Precision For Medicine

In Focus: lung cancer

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Emerging treatment options for pancreatic cancer with Thomas Seufferlein

Features

Interviews

Spotlights

Journal articles

Stay up to date

Oncology Central Newsletter